A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

Trial Profile

A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs ALKS 8700 (Primary) ; Dimethyl fumarate
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms EVOLVE-2; EVOLVE-MS; EVOLVE-MS-2
  • Sponsors Alkermes plc
  • Most Recent Events

    • 27 Nov 2017 According to a Biogen media release, initial data from EVOLVE-MS-2 are expected in the first half of 2018.
    • 28 Oct 2017 Patient demographics and baseline characteristics as of September 2017 will be presented as per trial design presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Trial design presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top